Date: 2016-06-23
Type of information: Nomination
Compound:
Company: Momenta Pharmaceuticals (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 23, 2016, Momenta Pharmaceuticals announced the appointment of Steven C. Gilman , Ph.D. to its Board of Directors effective June 22, 2016 . Dr. Gilman was most recently Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals , until its acquisition by Merck & Co. in January 2015 . Dr. Gilman currently serves as the Executive Chairman and interim CEO of ContraFect Corporation and as a member of the board of directors of Vericel, Scynexis and Keryx. He also serves as a member of the board of directors of the Northeastern University Drug Discovery Advisory Board , the Massachusetts Biotechnology Association and the Penn State University Biotechnology Advisory Board . Prior to joining Cubist, Dr. Gilman served as Chairman of the Board of Directors and CEO of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc. , where he held a number of senior leadership roles including Vice President and General Manager of the Inflammation Franchise. Prior to Millennium, he was Group Director at Pfizer Central Research , where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation , Temple University School of Medicine , and Connecticut College . Dr. Gilman received his Ph.D. and M.S. degrees in microbiology from Pennsylvania State University , his post-doctoral training at Scripps Clinic and Research Foundation , and received a B.A. in microbiology from Miami University of Ohio . Momenta also announced that Bennett M. Shapiro , M.D., will no longer serve as a member of Momenta's Board of Directors following completion of his term ending on June 22, 2016 . Dr. Shapiro was a member of the Board of Directors since 2003, serving on the science, compensation, and nominating and corporate governance committees.
Financial terms:
Latest news:
